Publication
Number of items: 22.
None
  • Disruption of D-alanyl esterification of Staphylococcus aureus cell wall teichoic acid by the {beta}-lactam resistance modifier (-)-epicatechin gallate. (2009) Patricia Bernal, Mire Zloh and Peter W. Taylor
    • Public
  • SMT19969 as a treatment for Clostridium difficile infection : an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. (2015) Simon D. Baines, G. S. Crowther, J. Freeman, S. Todhunter, R. Vickers and M. H. Wilcox
  • In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. (2007) T. Garnier, A. Mantyla, T. Jarvinen, J. Lawrence, Marc Brown and S.L. Croft
    • Restricted
  • Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. (2013) Simon D. Baines, Caroline H. Chilton, Grace S. Crowther, Sharie L. Todhunter, Jane Freeman and Mark H. Wilcox
  • Mixed infection by Clostridium difficile in an in vitro model of the human gut. (2013) Simon D. Baines, Grace S. Crowther, Sharie L. Todhunter, Jane Freeman, Caroline H. Chilton, Warren N. Fawley and Mark H. Wilcox
  • Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. (2005) Simon D. Baines, Jane Freeman and Mark H. Wilcox
  • Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. (2011) Simon D. Baines, Alan R. Noel, Grace S. Huscroft, Sharie L. Todhunter, Rachael O'Connor, Joanne K. Hobbs, Jane Freeman, Andy M. Lovering and M. H. Wilcox
  • Emergence of reduced susceptibility to metronidazole in Clostridium difficile. (2008) Simon D. Baines, Rachael O'Connor, Jane Freeman, Warren N Fawley, Celine Harmanus, Paola Mastrantonio, Ed J. Kuijper and M. H. Wilcox
  • Mecillinam : a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. (2009) Simon D. Baines, Rachael O'Connor, Grace Huscroft, Katie Saxton, Jane Freeman and Mark H Wilcox
  • Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. (2008) Simon D. Baines, Rachael O'Connor, Katie Saxton, Jane Freeman and Mark H. Wilcox
  • Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. (2009) Simon D. Baines, Rachel O'Connor, Katie Saxton, Jane Freeman and M. H. Wilcox
  • Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. (2006) Simon D. Baines, Katie Saxton, Jane Freeman and Mark H. Wilcox
  • In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. (2013) C. H. Chilton, G. S. Crowther, Simon D. Baines, S. L. Todhunter, J. Freeman, H. H. Locher, A. Athanasiou and M. H. Wilcox
  • Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. (2013) C. H. Chilton, J. Freeman, Simon D. Baines, G. S. Crowther, S. Nicholson and M. H. Wilcox
  • In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. (2015) D. Corbett, A. Wise, S. Birchall, P. Warn, Simon D. Baines, G. Crowther, J. Freeman, C. H. Chilton, J. Vernon, M. H. Wilcox and R. J. Vickers
  • Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. (2014) Grace S. Crowther, Caroline H. Chilton, Sharie L. Todhunter, Scott Nicholson, Jane Freeman, Simon D. Baines and Mark H. Wilcox
  • Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. (2013) Grace S Crowther, Simon D. Baines, Sharie L Todhunter, Jane Freeman, Caroline H Chilton and Mark H Wilcox
  • Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. (2005) Jane Freeman, Simon D. Baines, Daniela Jabes and Mark H. Wilcox
  • Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. (2007) Jane Freeman, Simon D. Baines, Katie Saxton and Mark H. Wilcox
  • Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. (2011) Jane Freeman, Simon D. Baines, Sharie L. Todhunter, Grace S. Huscroft and M. H. Wilcox
  • Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. (2005) Jane Freeman, Joanna Stott, Simon D. Baines, Warren N. Fawley and Mark H. Wilcox
  • In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. (2008) Rachael O'Connor, Simon D. Baines, Jane Freeman and Mark H. Wilcox